HIV Viral Suppression With Unintentional Lenacapavir Monotherapy in Adherence-Challenged Patients: A Case Series

Authors:

Abstract
Lenacapavir, a long-acting human immunodeficiency virus (HIV) capsid inhibitor, is thought to have a low resistance barrier based on current, limited data. We describe 4 patients experiencing homelessness with severe mental illness who maintained HIV suppression (<30 copies/mL) despite unintentional receipt of lenacapavir monotherapy for 9–38 weeks, highlighting its potential among adherence-challenged populations.
Funding Information
  • National Center for Advancing Translational Sciences (2KL2TR001870)
  • National Institute of Allergy and Infectious Diseases (5R37AI098472)

This publication has 11 references indexed in Scilit: